LABT

← Markets

LABTLakewood-Amedex Biotherapeutics Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Wed, Aug 26
8:26 AMYahooLABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers
Tue, Aug 25
4:36 PMYahooLakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company
Wed, Jul 22
7:02 AMYahooLakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Wed, Jul 15
7:02 AMYahooLakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Mon, Jul 13
11:35 AMYahooCEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics
Tue, Jul 7
7:02 AMYahooLakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Thu, Jun 25
7:02 AMYahooLakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
Tue, Jun 23
4:20 AMYahooLABT: Initiating Coverage of Lakewood-Amedex; Building a Next-Generation Antimicrobial Platform
Mon, Jun 22
7:02 AMYahooLakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
Tue, Jun 16
7:02 AMYahooLakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Wed, May 27
7:02 AMYahooLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Mon, May 18
7:02 AMYahooLakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers